Denali Therapeutics Inc. (4DN)
FSX
Closed
Oct 8, 2026
Day's Range
16.8952 wk Range
12.31Overview - 4DN - Denali Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
1.97B
P/E (Trailing)
‪-6.13‬
P/E (Forward)
‪-8.02‬
PEG Ratio
‪1.10‬
Price / Sales (TTM)
‪808.32‬
Price / Book
‪3.96‬
EV / EBITDA
‪-4.25‬
Profitability
Gross Margin
‪97.41%‬
Profit Margin
‪0.00%‬
Operating Margin
‪-3,601.30%‬
Return on Assets
‪-29.14%‬
Return on Equity
‪-54.92%‬
Ownership
Shares Outstanding
159.75M
Float
155.09M
Held by Insiders
‪9.08%‬
Held by Institutions
‪101.36%‬
Price stats
Beta
‪1.00‬
50-Day Avg
‪19.84‬
200-Day Avg
‪18.06‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 4DN - Denali Therapeutics Inc.
Peers - 4DN - Denali Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
Profile Summary - 4DN - Denali Therapeutics Inc.
About
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions such as Alzheimer's disease, Parkinson's disease, and other rare…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
